2L Treatment of EGFR-Positive NSCLC
Update: 2025-02-18
Description
Practically Speaking: Mariposa-2. In this episode of MedOncNow, Dr. Barb Melosky joins Dr. Kassam to discuss the use of Amivantimab + Carboplatin + Pemetrexed in the second-line treatment of EGFR-positive non small cell lung cancer (NSCLC) progressing after Osimertinib.
A timely discussion, given that Johnson & Johnson now has a compassionate access program for this regimen.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
